Sugar-based compounds could lead to ways to bypass antibiotic resistance

March 8, 2018, Washington University School of Medicine in St. Louis
Green marks the spots where a bacterial protein binds to human kidney tissues, a key step in urinary tract infections. Researchers at the School of Medicine have designed sugar molecules that block the bacteria from binding, allowing them to be washed out of the urinary tract. The compounds represent a step toward treating UTIs without antibiotics. Credit: Vasilios Kalas

Half of all women will experience the pain and burning of a urinary tract infection (UTI) at some point in their lives. Most such infections can be successfully treated with antibiotics, but antibiotic resistance – the ability of bacteria to withstand antibiotics – is a growing problem.

Now, researchers at Washington University School of Medicine in St. Louis report they have found a way to treat UTIs without using , at least in mice. The study is published March 5 in Proceedings of the National Academy of Sciences.

"Millions of women every year suffer UTIs, and they're getting harder to treat," said co-senior author Scott J. Hultgren, the Helen L. Stoever Professor of Molecular Microbiology. "We've shown that just by blocking the from adhering to the mice's urinary tracts, we can treat the infection. This is a new way of approaching the problem of ."

The bacteria Escherichia coli (E. coli) cause 80 percent of UTIs, leading to painful, burning urination. The bacteria then sometimes travel to the kidneys, causing back pain and fever. In rare cases, they spread to the blood, a potentially lethal complication.

Often, UTIs can be cleared up with antibiotics, but 10 to 20 percent of cases do not respond to current first-line drugs. Hultgren and his colleagues are working on an alternative that would prevent bacteria from causing disease, which may help reduce dependency on antibiotics.

E. coli's first step in causing UTIs is to latch onto sugars on the surface of the bladder with long, hairlike structures called pili. Hultgren and co-senior author James W. Janetka, an associate professor of biochemistry and molecular biophysics, previously created mannosides, modified forms of a sugar called mannose, that the bacteria favor over typical sugars on the bladder wall. When mice with UTIs were given the mannosides, the E. coli in their bladders grabbed hold of those molecules and were swept away.

Recently, Matthew Conover, a postdoctoral researcher in Hultgren's lab, and colleagues showed that E. coli also can latch onto galactose, another sugar molecule found on urinary tissues.

Vasilios Kalas, an MD/Ph.D. student in Hultgren's lab, worked in collaboration with Janetka to design and screen modified forms of galactose known as galactosides to find versions that attach firmly to the adhesive proteins at the end of the bacteria's pili. Using X-ray snapshots of galactosides bound to the adhesive protein as a guide, they synthesized even stickier versions of these molecules. Then, they pitted each new galactoside against galactose in a competition to see which attached best to the bacterial protein. Galactosides that outcompete galactose may be able to serve as decoys, they reasoned, tricking bacteria into catching hold of a floating galactoside instead of a urinary tract-anchored galactose.

The researchers studied whether a galactoside could help treat a UTI. They injected E. coli into the bladders of mice and then gave the mice either the galactoside or a placebo. The numbers of bacteria in the bladders and kidneys of mice given the galactoside dropped by up to a hundredfold.

When mice were simultaneously treated with a mannoside and the galactoside, the bacteria in their bladders dropped a thousandfold, and the bacteria in their kidneys were nearly eradicated.

"We showed that we can administer two different inhibitors and see a synergistic therapeutic effect," said Kalas, the paper's first author. "The data suggest that both types of pili play a role in attachment during infection."

The pilus that attaches to mannose plays a bigger role in the bladder, while the pilus that recognizes galactose seems to be more important in the kidneys. Foiling the bacteria's attempts to grasp both sugars could target both uncomplicated and serious bladder and kidney infections.

A drug that undermines the bacteria's ability to stay in the body is less likely to drive resistance because, unlike antibiotics, it would not force bacteria to die or evolve resistance in order to survive, the researchers said.

"We're not killing them, we're just helping flush them out of certain environments where they can do damage," Kalas said.

The researchers also demonstrated that the galactoside prevented the bacteria's adhesive protein from sticking to human kidney tissue.

Before the galactoside can enter human trials, further work is needed to show that it is not toxic and can be absorbed into the circulation when taken by mouth. Nevertheless, the researchers are confident they have taken an important step toward developing alternatives to antibiotics.

"With this paper, we have now successfully targeted two different sugar-protein interactions with a proven strategy," Janetka said. "The first step for many disease-causing bacteria is to bind a sugar on a body surface, so this same antibiotic-sparing approach could be applied to other pathogens besides E. coli. If we can identify other that bacteria use to stick to specific sites in the human body, in many cases we should be able to design compounds to inhibit their binding."

Explore further: New treatment reduces E. coli, may offer alternative to antibiotics

More information: Vasilios Kalas et al. Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1720140115

Related Stories

New treatment reduces E. coli, may offer alternative to antibiotics

June 14, 2017
Urinary tract infections (UTIs) are among the most common infections, and they tend to come back again and again, even when treated. Most UTIs are caused by E. coli that live in the gut and spread to the urinary tract.

Researchers identify protein critical in causing chronic urinary tract infections

September 22, 2016
Researchers have identified a potential way to prevent chronic urinary tract infections (UTIs). Their research points to a key protein that bacteria use to latch onto the bladder and cause UTIs, according to scientists at ...

Experimental drug clears chronic urinary infections in mice

November 16, 2011
An experimental treatment for urinary tract infections has easily passed its first test in animals, alleviating weeks-long infections in mice in as little as six hours.

Human urine helps prevent bacteria from sticking to bladder cells

June 30, 2015
Human urine contains factors that prevent a common culprit in urinary tract infections (UTIs), uropathogenic Escherichia coli bacteria, from properly attaching to bladder cells, a necessary step for infection. The research, ...

Vaginal bacteria can trigger recurrent UTIs, study shows

March 30, 2017
About half of all women will experience urinary tract infections in their lifetimes, and despite treatment, about a quarter will develop recurrent infections within six months of initial infection.

Recommended for you

LincRNAs identified in human fat tissue

June 21, 2018
A large team of researchers from the U.S. and China has succeeded in identifying a number of RNA fragments found in human fat tissue. In their paper published in the journal Science Translational Medicine the group describes ...

Scientists solve the case of the missing subplate, with wide implications for brain science

June 21, 2018
The disappearance of an entire brain region should be cause for concern. Yet, for decades scientists have calmly maintained that one brain area, the subplate, simply vanishes during the course of human development. Recently, ...

Key molecule of aging discovered

June 21, 2018
Every cell and every organism ages sooner or later. But why is this so? Scientists at the German Cancer Research Center in Heidelberg have now discovered for the first time a protein that represents a central switching point ...

Compound made inside human body stops viruses from replicating

June 20, 2018
The newest antiviral drugs could take advantage of a compound made not by humans, but inside them. A team of researchers has identified the mode of action of viperin, a naturally occurring enzyme in humans and other mammals ...

Research reveals zero proof probiotics can ease your anxiety

June 20, 2018
If you're expecting probiotics to reduce your anxiety, it might be time to put down that yogurt spoon—or supplement bottle—and call a professional instead.

Long-term estrogen therapy changes microbial activity in the gut, study finds

June 20, 2018
Long-term therapy with estrogen and bazedoxifene alters the microbial composition and activity in the gut, affecting how estrogen is metabolized, a new study in mice found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.